BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 10479285)

  • 1. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.
    Schiller PW; Weltrowska G; Berezowska I; Nguyen TM; Wilkes BC; Lemieux C; Chung NN
    Biopolymers; 1999; 51(6):411-25. PubMed ID: 10797230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.
    Weltrowska G; Nguyen TM; Chung NN; Wilkes BC; Schiller PW
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5082-5. PubMed ID: 23932788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
    Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
    J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
    Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid peptide-derived analgesics.
    Schiller PW
    AAPS J; 2005 Oct; 7(3):E560-5. PubMed ID: 16353933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
    Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
    Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric opioid peptide with mixed mu agonist/delta antagonist properties.
    Weltrowska G; Lemieux C; Chung NN; Schiller PW
    J Pept Res; 2004 Feb; 63(2):63-8. PubMed ID: 15009527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
    Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
    Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
    J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
    Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series.
    Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A
    Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
    Liu JG; Prather PL
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist Activity of the delta-antagonists TIPP and TIPP-psi in cellular models expressing endogenous or transfected delta-opioid receptors.
    Martin NA; Terruso MT; Prather PL
    J Pharmacol Exp Ther; 2001 Jul; 298(1):240-8. PubMed ID: 11408548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.